BMS 453

Key Product Details

Product Description

BMS 453 is a synthetic retinoid. Retinoic acid receptor β (RARβ) agonist in vivo; RARα and RARγ antagonist in vitro. Inhibits breast cell proliferation by inducing active transforming growth factor β (TGFβ) and causes G₁ arrest.

Product Specifications for BMS 453

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BMS 453

The following data is based on the product molecular weight 380.48.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.63 mL	13.14 mL	26.28 mL
5 mM	0.53 mL	2.63 mL	5.26 mL
10 mM	0.26 mL	1.31 mL	2.63 mL
50 mM	0.05 mL	0.26 mL	0.53 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 18 publications citing the usage of this product.

• Yang The retinoic acid receptor antagonist, BMS543, inhibits normal breast cell growth by inducing active TGFB and causing cell cycle arrest. Oncogene 2001 PMID: 11753686
• Monteiro Commitment of mouse embryonic stem cells to the adipocyte lineage requires retinoic acid receptor beta and active GSK3. Stem Cells Dev. 2009 PMID: 18690793
• Chen RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995 PMID: 7720709

Product Documents for BMS 453